Inhaled nitric oxide lowers pulmonary capillary pressure (PCP) in animals and in patients with acute respiratory distress syndrome (ARDS). A dose-response relationship in patients with ARDS has not yet been established. Therefore, we studied the effects of four concentrations of nitric oxide (1, 10, 20 and 40 volumes per million (vpm)) in random order, on PCP in 19 patients with ARDS. PCP was estimated by visual analysis of the pressure decay curve after balloon inflation of the pulmonary artery catheter. Haemodynamic and gas exchange variables were measured at each nitric oxide concentration. Patients were classified as responders when PCP decreased by at least 2 mm Hg after nitric oxide 20 vpm. In responders (n:8), nitric oxide decreased PCP and post-capillary vascular resistance dose-dependently and changed longitudinal distribution of pulmonary vascular resistance with a maximum effect at 20 vpm. In non-responders (n:11), PCP did not change. In both groups, the nitric oxide-induced decrease in pre-capillary vascular resistance was small with a maximum effect at 1 vpm. In ARDS, vasodilatation of pre-capillary vessels is achieved at low concentrations of nitric oxide, whereas the effect of nitric oxide on postcapillary vessels is variable. Higher concentrations may be required for optimal post-capillary vasodilatation in a subgroup of ARDS patients. (Br.
Inhaled nitric oxide lowers pulmonary capillary pressure (PCP) in animals and in patients with acute respiratory distress syndrome (ARDS). A dose-response relationship in patients with ARDS has not yet been established. Therefore, we studied the effects of four concentrations of nitric oxide (1, 10, 20 and 40 volumes per million (vpm)) in random order, on PCP in 19 patients with ARDS. PCP was estimated by visual analysis of the pressure decay curve after balloon inflation of the pulmonary artery catheter. Haemodynamic and gas exchange variables were measured at each nitric oxide concentration. Patients were classified as responders when PCP decreased by at least 2 mm Hg after nitric oxide 20 vpm. In responders (n:8), nitric oxide decreased PCP and post-capillary vascular resistance dose-dependently and changed longitudinal distribution of pulmonary vascular resistance with a maximum effect at 20 vpm. In non-responders (n:11), PCP did not change. In both groups, the nitric oxide-induced decrease in pre-capillary vascular resistance was small with a maximum effect at 1 vpm. In ARDS, vasodilatation of pre-capillary vessels is achieved at low concentrations of nitric oxide, whereas the effect of nitric oxide on postcapillary vessels is variable. Higher concentrations may be required for optimal post-capillary vasodilatation in a subgroup of ARDS patients. (Br. J. Anaesth. 1998; 80: 440-446) Keywords : lung, acute respiratory distress syndrome; pharmacology, nitric oxide; lung, vasculature Arterial hypoxaemia and bilateral infiltrates on the chest radiograph in the absence of left atrial hypertension are features of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Transvascular fluid filtration depends on the filtration coefficient, reflection coefficient and on hydrostatic and oncotic pressure differences. 2 In the presence of a capillary leak, as occurs in ALI and ARDS, the reflection coefficient approaches zero and intracapillary hydrostatic pressure becomes the decisive force in governing transvascular fluid filtration, that is oedema formation. In ALI and ARDS, constriction of post-capillary vessels may result in increased pulmonary capillary pressure (PCP) 3-9 with enhancement of oedema formation. Thus one of the therapeutic goals in the treatment of ALI and ARDS is reduction of PCP.
Inhaled nitric oxide, a selective pulmonary vasodilator, [10] [11] [12] has been shown to decrease PCP in animal models of pulmonary hypertension 13 14 and in patients with ALI. 15 Inhaled nitric oxide decreases transvascular fluid filtration in rabbit lungs with oxidant-induced lung injury, 16 in isolated rat lungs with neutrophil-mediated capillary leak 17 and in hydrogen peroxide-challenged rabbit lungs. 18 In patients with ALI, nitric oxide 40 volumes per million (vpm) reduced PCP and transvascular albumin flux. 15 19 Recently, nitric oxide has been shown to decrease pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR) at concentrations lower than 40 vpm. [20] [21] [22] The effect of lower nitric oxide concentrations on PCP, however, has not been studied in patients with ALI or ARDS. Therefore, we have investigated the effect of different nitric oxide concentrations on PCP and on longitudinal distribution of PVR in 19 patients with ARDS.
Patients and methods
After obtaining approval from the local Ethics Committee and written consent from the patient's family, we studied 19 consecutive patients with no history of previous lung disease who fulfilled the criteria of ARDS. 1 The clinical characteristics of the patients are summarized in table 1. The severity of acute lung disease was graded by Murray's lung injury score. 23 The severity of critical illness and additional organ failures were classified by the acute physiology and chronic health evaluation II (APACHE II) score 24 and an organ system failure score. 25 According to this score, dysfunctions of five organ systems were identified: liver dysfunction (i.e. serum bilirubin concentration 934 mol litre 91 or serum transaminase concentrations three times normal, or both), renal dysfunction (i.e. serum creatinine concentration 9177 mol litre 91 ), coagulation disorders (with or without actual bleeding), host defence failure (i.e. sepsis diagnosed by positive blood cultures) and cardiovascular failure (i.e. catecholamines were required to support systemic circulation). Leucocyte count in peripheral blood and the results of bacteriological examination of tracheal aspirates from the day of study or 1 day before, were recorded as markers of infection.
Patients' lungs were ventilated using a pressurecontrolled setting (Servo ventilator 900 C, Siemens Elema, Lund, Sweden) with tidal volumes of 4.9-12.8 ml/kg body weight, ventilatory frequencies . In all patients, a pulmonary artery thermodilution catheter (model SP 1507, Spectramed, Düsseldorf, Germany or Opticath P7110-EP8, Abbott, Wiesbaden, Germany) and a radial arterial catheter were inserted. Systolic, diastolic and mean pulmonary artery pressure (PAP), central venous pressure (CVP), systolic, diastolic and mean arterial pressure (MAP), and heart rate (HR) were monitored continuously. Cardiac output (CO) was determined as the mean of three thermodilution measurements performed randomly during the respiratory cycle using saline 10 ml at room temperature and a cardiac output computer (Sirecust 1281, Siemens, Erlangen, Germany). All pressure measurements were performed at end-expiration with the patient supine and the calibrated pressure transducers (Medex Novotrans II MX 860, Hilliard, OH, USA) zeroed to atmospheric pressure at the midaxillary level. In all patients pulmonary artery wedge pressure (PAWP) was higher than PEEP, suggesting a zone III position of the tip of the pulmonary artery catheter. PCP was estimated by visual analysis of the pressure decay curve after pulmonary artery occlusion, as described by Cope and colleagues. 26 Pulse pressure was reduced by a small container with 0.4 ml of air attached to the side port of the pulmonary artery catheter. When PAP was stable, the balloon of the pulmonary artery catheter was inflated and the pressure profile recorded on a printer (Sirenet, Siemens, Erlangen, Germany) at a chart speed of 6.25 mm s 91 until wedge pressure was obtained. The inflexion point, that is PCP, was determined visually by placing a ruler on the rapid component of the pressure decline adjusted for the best fit and marking the point at which the slow component of the pressure profile deviated from the rapid component ( fig. 1 ). Pressure tracings were recorded at endexpiration using the "expiratory halt" function of the Servo 900 C ventilator for 5-8 s to suppress respiratory artefacts. Three pressure profiles were obtained with each set of measurements. Pressure tracings were analysed separately by two independent investigators (H. K. and A. B.) and the means of the measurements were used for further calculations. The coefficient of variation of the PCP estimation was :4%. After determination of PAP, PCP and PAWP, PVR was calculated using standard formulae and divided into pre-capillary and post-capillary resistance. Pulmonary pre-capillary resistance (PVR art ) was calculated as the pulmonary pre-capillary pressure gradient (PAP-PCP) times 80 divided by CO, and pulmonary post-capillary resistance (PVR ven ) as the pulmonary post-capillary pressure gradient (PCP-PAWP) times 80 divided by CO. Arterial and mixed venous blood-gas tensions, haemoglobin oxygen saturation, total haemoglobin concentration and packed cell volume were determined using an ABL 510 (Radiometer, Copenhagen, Denmark). Nitric oxide was administered as described previously. 15 Briefly, during inspiration, nitric oxide was delivered from a gas tank containing nitric oxide 600 vpm in nitrogen (Messer Griesheim, Rheinfelden, Germany) and fed into the inspiratory limb of the ventilator tubing, 90 cm proximal of the Y-piece. A magnetic valve connected to the ventilator allowed flow of nitric oxide-nitrogen only during inspiration. Nitric oxide and nitrogen dioxide concentrations were measured by a chemiluminescent analyser (Al Med 700, ECO Physics, Dürnten, Switzerland) connected to the inspiratory limb of the ventilator tubing, 40 cm proximal of the Y-piece. After baseline measurements, four inspiratory nitric oxide concentrations (1, 10, 20 and 40 vpm) were administered in random order. Haemodynamic and gas exchange variables were measured at each nitric oxide concentration after an equilibration period of 30 min. Thirty minutes after cessation of inhalation of nitric oxide, measurements were repeated. Methaemoglobin was measured photometrically.
Patients were classified as responders (n:8) when PCP decreased by at least 2 mm Hg after nitric oxide 20 vpm. In non-responders (n:11), PCP decreased by less than 2 mm Hg at nitric oxide 20 vpm.
Data are expressed as mean (SD) unless otherwise indicated. The effects of nitric oxide on haemodynamic and gas exchange variables, except for preand post-capillary pressure gradients and PVR art and PVR ven , respectively, were analysed using two-way analysis of variance (ANOVA) for repeated measurements with one within-subject factor (nitric oxide concentration) and one between-subject factor (responder and non-responder). The effect of different nitric oxide concentrations on pre-and post-capillary pressure gradients, and on PVR art and PVR ven were analysed by ANOVA for repeated measurements with two within-subject factors (nitric oxide concentration and localization, i.e. pre-capillary and post-capillary) and one between-subject factor (responder and non-responder). The incidence of additional organ failures and laboratory findings of responders and non-responders were compared by one-way ANOVA. P:0.05 was considered statistically significant.
Results
Median lung injury score in patients was 3.25 (range 2-3.5).
In eight patients, PCP decreased by at least 2 mm Hg after nitric oxide 20 vpm (responders). In Table 2 Haemodynamic and gas exchange variables of responders and non-responders at different NO concentrations. Responders : Patients responding with a decrease in pulmonary capillary pressure of at least 2 mg Hg at inhaled nitric oxide 20 vpm, non-responders : patients with a decrease in pulmonary capillary pressure of less than 2 mm Hg at inhaled nitric oxide 20 vpm, NO : inhaled nitric oxide, PAP : mean pulmonary artery pressure, PCP : pulmonary capillary pressure, PAWP : pulmonary artery wedge pressure, CO : cardiac output, PVR : pulmonary vascular resistance, 11 (2) 11 (2) 11 (2) 11 (2) 11 (2) 11 (2) the remaining 11 patients, PCP decreased by less than 2 mm Hg after nitric oxide 20 vpm (nonresponders). In responders, PAP, PCP and total PVR decreased during inhalation of nitric oxide (table 2) , with a maximum effect at nitric oxide 20 vpm. PAWP and cardiac index remained constant (table 2) . PAP-PCP and PVR art decreased slightly after nitric oxide 1 vpm (ns), with no further decline at higher nitric oxide concentrations ( fig. 2A, B) . PCP-PAWP and PVR ven decreased dose-dependently at nitric oxide concentrations up to 20 vpm ( fig. 3A, B) . The contribution of PVR ven to total PVR decreased with increasing concentration of inhaled nitric oxide and was different from baseline at 20 and 40 vpm (fig. 4) . The mean increase in 2 
2
O O I a / P F was highest at 1 vpm with a further slight increase at 10 vpm (table 2) . Values before and after administration of nitric oxide were not different.
In non-responders, PAP at baseline was slightly but not significantly lower than in responders ( Whereas PAP-PCP and PVR art of non-responders were similar to corresponding values of responders at either nitric oxide concentration ( fig. 2A, B) , PCP-PAWP and PVR ven of non-responders were lower at baseline and at nitric oxide 1 and 10 vpm compared with responders ( fig. 3A, B) . APACHE II scores (18.4 (3. 3) in responders vs 17.3 (4.0) in non-responders), and incidence of additional organ failures, that is liver dysfunction (five of eight responders vs five of 11 nonresponders), renal dysfunction (two of eight responders vs two of 11 non-responders), coagulation disorders (five of eight responders vs seven of 11 non-responders), host defence failure (none of all 
Discussion
The major findings of this study were that in a subgroup of ARDS patients (responders), nitric oxide decreased PCP in a dose-dependent manner with a maximum effect at 20 vpm. In responders, baseline capillary pressure was high compared with non-responders. Also, in responders, inhaled nitric oxide acted differently on pre-and post-capillary vasculature. In addition, nitric oxide changed the longitudinal distribution of PVR only at higher concentrations (20 vpm) .
PAP is increased in ALI and ARDS because of release of vasoactive mediators, microthrombosis, vascular compression and hypoxic pulmonary vasoconstriction. 27 The sites of hypoxic pulmonary vasoconstriction and microthrombosis are precapillary vessels, 28 29 whereas vasoactive mediators constrict post-capillary vessels also. 3 4 6 7 9 Pulmonary venoconstriction results in an increase in PCP. In the presence of a capillary leak, as occurs in ALI and ARDS, PCP becomes the decisive determinant of fluid filtration, that is oedema formation. 2 Grimbert, Parker and Taylor have shown in acid-injured dog lungs that an increase in PCP by 3 mm Hg results in an eight-fold increase in pulmonary transvascular fluid filtration. 30 Therefore, reduction of PCP is one of the therapeutic goals in the treatment of ARDS.
Inhaled nitric oxide, a selective pulmonary vasodilator, has been shown to decrease PCP in bloodperfused rabbit lungs preconstricted with a stable thromboxane analogue, 14 in rat lungs preconstricted with endothelin 13 and in patients suffering from ALI and ARDS. 15 19 31 In both animal models of pulmonary hypertension, the NO-induced decrease in PCP was not parallelled by a change in longitudinal distribution of PVR suggesting a similar vasodilatating effect of nitric oxide on pre-and post-capillary vessels. Moreover, in isolated rabbit lung preparations, the degree of pre-and post-capillary vasodilatation did not increase with increasing nitric oxide concentration 14 whereas in isolated, endothelin preconstricted rat lungs, nitric oxide 670 vpm inhibited pre-capillary vasoconstriction slightly more than nitric oxide 170 vpm. 13 Other investigators found in isolated rabbit lungs preconstricted with a stable thromboxane analogue that inhaled nitric oxide 120 vpm decreased only pre-capillary resistance with no effect on post-capillary resistance. 32 In patients with ARDS, however, nitric oxide 40 vpm decreased post-capillary vascular resistance to a greater extent than pre-capillary resistance suggesting a predominant vasodilatating effect on post-capillary vessels. 15 19 Comparing the effects of nitric oxide 15 and 25 vpm in seven patients with ARDS, Rossetti, Guénard and Gabinski 31 found a significant decrease in PVR ven only during inhalation of nitric oxide 25 vpm.
In healthy lungs, post-capillary vascular resistance accounts for approximately 40% of total vascular resistance. 33 In our patients, who responded to nitric oxide inhalation with a significant decrease in PCP, baseline contribution of post-capillary PVR to total vascular resistance was high (54%). In these patients, nitric oxide dilated post-capillary vessels dosedependently up to 20 vpm whereas pre-capillary vascular resistance decreased slightly at 1 vpm nitric oxide. In contrast with responders, baseline PVR ven / PVR of non-responders was normal (35%) and inhalation of nitric oxide did not influence longitudinal distribution of PVR.
The different findings between animal studies and patients with ALI and ARDS may be explained by species differences and characteristics of the animal models. 34 35 Inhaled nitric oxide dilates preconstricted pulmonary vessels but has no effect on vessels at normal tone. 11 36 In isolated rabbit lungs, infusion of a thromboxane analogue caused a marked increase in pre-capillary resistance. In contrast, the increase in post-capillary resistance was relatively small.
14 In isolated rat lungs, endothelin-induced vasoconstriction was more pronounced in pre-capillary than in post-capillary vessels. 13 Reversing flow in thromboxane preconstricted rabbit lungs resulted in a marked increase in pulmonary venous resistance. 32 Under those circumstances, inhaled nitric oxide dilated post-capillary vessels. In KCL preconstricted bovine pulmonary vessels, nitric oxide dilated veins more than arteries. 37 Thus the different effects of inhaled nitric oxide in this study may be the result of a variable degree of pulmonary venoconstriction in patients with ARDS. Longitudinal distribution of PVR tends to normalize during inhalation of nitric oxide. When pulmonary venoconstriction is pronounced, inhalation of nitric oxide results in a marked venodilatation with a concomitant decrease in PCP. In that instance, higher nitric oxide concentrations (20 vpm) are necessary for optimal venodilatation.
In our study, responders and non-responders were not different with regard to gas exchange, cardiac output, ventricular filling pressures, APACHE II score 24 or incidence of organ dysfunction. 25 In our small group of patients the underlying disease did not influence the response to inhaled nitric oxide. Leucocyte count, however, was higher in responders than in non-responders. In isolated, TNF␣-challenged guinea pig lungs, perfusion with neutrophil enriched perfusate increased PCP from 6.0 to 12.8 cm H 2 O. 38 Post-capillary vascular resistance increased from 0.075 to 0.339 cm H 2 O ml 91 min 91 whereas pre-capillary resistance was unchanged. 38 In isolated rat lungs, perfusion with PMA-activated leucocytes resulted in pulmonary hypertension and an increase in PCP. 39 Post-capillary resistance increased significantly but the increase in pre-capillary vascular resistance was not significant. Thus in our patients leucocytes may have contributed to the differences in longitudinal distribution of PVR values of responders and non-responders.
The effect of nitric oxide on pre-capillary vascular resistance was relatively small. The small decrease in PVR art during inhalation of nitric oxide may be the result of a relatively modest vasoconstriction of precapillary vessels. Moreover, as nitric oxide inactivation by haemoglobin is inversely related to oxygen saturation, 40 nitric oxide may be inactivated more effectively in pre-capillary than in post-capillary vessels.
A possible limitation of our study was the technique used to estimate PCP. Standard techniques for measurement of PCP are micropuncture 41 and the isogravimetric method. 42 Vascular occlusion methods correlate well with the isogravimetric method for measuring microvascular pressure in isolated lung preparations. [43] [44] [45] These methods, [41] [42] [43] [44] [45] however, cannot be applied to intact lungs. Analysis of PAP decay after balloon inflation has been used in intact lungs under the premise that balloon inflation in the in situ lung is equivalent to arterial occlusion in the isolated lung. 26 43 Although it has been demonstrated that analysis of the pressure decay curve appears to be a valid method for estimating PCP 26 43 45 and that visual analysis of the pressure decay curve is an adequate approach for estimating PCP, 26 46 analysis of pressure decay profiles remains a subject of debate. 47 48 This study may have clinical implications. In the presence of a capillary leak, PCP is the major factor determining transvascular fluid filtration.
2 Inhaled nitric oxide has been shown to reduce transvascular fluid flux in rabbit lungs with oxidant-induced lung injury, 16 in isolated rat lungs with neutrophilmediated capillary leak 17 and in hydrogen peroxide challenged rabbit lungs. 18 In patients with ALI, nitric oxide 40 vpm inhibited transvascular albumin flux. 19 The decrease in transvascular albumin flux correlated well with the NO-induced decrease in PVR ven . As we have now demonstrated that PCP decreases with nitric oxide 10 and 20 vpm, transvascular fluid flux may be reduced at nitric oxide concentrations lower than 40 vpm. A dose-response of nitric oxide on transvascular flux has yet to be established.
The maximal effect of nitric oxide on 2 
2
O O I a / P F was observed at 1 vpm with a further slight but insignificant increase at 10 and 20 vpm. This finding is in agreement with previous studies. 21 22 49 50 It is worth noting that the maximum effect of inhaled nitric oxide on PVR art and on 2 
O O I a / P F was achieved at 1 vpm. As pre-capillary vessel tone is involved in the regulation of blood supply to the alveoli, it is possible that the increase in 2 O a P depends on the pre-capillary vasodilating action of nitric oxide.
The observed nitrogen dioxide concentrations after nitric oxide 10 and 20 vpm may have clinically relevant side effects in some patients. 51 Therefore, when administering nitric oxide concentrations of 10-20 vpm for prolonged periods, we would recommend nitrogen dioxide scavenging.
In summary, we found that in patients with ARDS, inhaled nitric oxide changed longitudinal distribution of PVR and decreased PCP when post-capillary vascular resistance was high. The maximum effect was achieved at nitric oxide 20 vpm.
